Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Interim Impact The Rise of Fractional Medical Affairs Roles in Pharmas New Reality
Summary
In this episode, Tom Caravela and Daniel Snyder explore the rise of fractional medical affairs roles in the post-COVID era. They define interim and fractional positions, highlighting how they benefit both job seekers and companies. The discussion covers the increase in these roles, company utilization of interim talent, disadvantages, and compensation expectations, offering negotiation tips for candidates. They also discuss the future of fractional staffing, market trends, and the gig economy's impact on pharma and biotech. The episode ends with cost-effective strategies and gratitude to the audience.
Key Points
- Fractional medical affairs roles offer a cost-effective solution for pharmaceutical companies to address specific project needs without committing to full-time hires. The rise in fractional positions is driven by economic uncertainties and the need for companies to streamline operations while still advancing critical projects. Engaging in fractional work can help professionals bridge employment gaps, expand their networks, and gain new therapeutic experience, making them more attractive in the job market.
fractional medical affairs roles, interim positions, gig economy in pharma, pharmaceutical staffing trends, fractional work benefits
Related Topics
You May Also Like
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care
Article
iNIZIO
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis